Blood biomarkers of inflammation and brain-derived neurotrophic factor can not be used to assess the effectiveness of collagen mesotherapy in chronic cervical myofascial pain syndrome. A pilot single-blind randomized study
Rheumatology International · 2026
DOI: 10.1007/s00296-026-06094-4 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Rheumatology International, 2026. Verfasst von Kamil Koszela und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Disorders, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland. kamil.aikido@interia.pl. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Collagen, Inflammation Mediators, Myofascial Pain Syndromes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. Prof. dr hab. med. Eleonory Reicher.
Abstract (Originalsprache)
Recent years have seen a marked increase in the number of patients diagnosed with spinal disorders, including chronic cervical myofascial pain syndrome (CMPS). This article aims to explore the potential of inflammatory process biomarkers in the blood and brain-derived neurotrophic factor (BDNF) as a means to assess the efficacy of collagen mesotherapy in the management of chronic CMPS. The second objective of this article is to evaluate the safety of collagen mesotherapy in chronic CMPS. The study comprised 23 subjects, who were randomly assigned either to the collagen mesotherapy group (n = 11) or the lignocaine mesotherapy group (n = 12). Blood was collected from each patient, and also the subjects were evaluated with the numerical rating scale (NRS) and the neck disability index (NDI).
Results
Both collagen and lignocaine mesotherapy have been observed to cause a significant reduction in pain intensity (NRS) and disability (NDI) over time, with no significant differences seen between the two interventions. However, the fluctuations in the levels of inflammatory biomarkers (TNFα, IL-1β, IL-6) and BDNF did not correspond with the clinical improvement noted. No adverse events related to the intervention were also observed. The potential of inflammatory biomarkers and BDNF, when assessed in blood serum, to serve as a basis for evaluating the efficacy of collagen mesotherapy in chronic CMPS; remains to be elucidated. Nevertheless, collagen mesotherapy appears to be an effective and safe treatment for chronic CMPS. However, further research in this area is required.
Trial registration
NCT06807177. https//clinicaltrials.gov/study/NCT06807177.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Musculoskeletal Disorders, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland. kamil.aikido@interia.pl.
- Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
- Early Arthritis Clinic, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
- Department of Internal Medicine, Rehabilitation and Physical Medicine, Medical University of Lodz, Łódź, Poland.
- Department of Neuroorthopedics and Neurology Clinic and Polyclinic, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
ORCID-Profile: Kamil Koszela, Agnieszka Paradowska-Gorycka, Brygida Kwiatkowska, Marta Woldańska-Okońska, Barbara Stypińska, Adam Ejma-Multański, Robert Gasik
Förderung
- Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. Prof. dr hab. med. Eleonory Reicher
Zitieren
APA
Koszela, K., Paradowska-Gorycka, A., Kwiatkowska, B., Woldańska-Okońska, M., Stypińska, B., Ejma-Multański, A., & Gasik, R. (2026). Blood biomarkers of inflammation and brain-derived neurotrophic factor can not be used to assess the effectiveness of collagen mesotherapy in chronic cervical myofascial pain syndrome. A pilot single-blind randomized study. Rheumatology International. https://doi.org/10.1007/s00296-026-06094-4
Vancouver
Koszela K, Paradowska-Gorycka A, Kwiatkowska B, Woldańska-Okońska M, Stypińska B, Ejma-Multański A, et al. Blood biomarkers of inflammation and brain-derived neurotrophic factor can not be used to assess the effectiveness of collagen mesotherapy in chronic cervical myofascial pain syndrome. A pilot single-blind randomized study. Rheumatology International. 2026. doi:10.1007/s00296-026-06094-4
BibTeX
@article{Koszela2026,
author = {Koszela, Kamil and Paradowska-Gorycka, Agnieszka and Kwiatkowska, Brygida and Woldańska-Okońska, Marta and Stypińska, Barbara and Ejma-Multański, Adam and Gasik, Robert},
title = {Blood biomarkers of inflammation and brain-derived neurotrophic factor can not be used to assess the effectiveness of collagen mesotherapy in chronic cervical myofascial pain syndrome. A pilot single-blind randomized study},
journal = {Rheumatology International},
year = {2026},
doi = {10.1007/s00296-026-06094-4}
}
EUVIMED